Position in GNLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$29,403
New position
Shares Held
12,150
first reported quarter
Ownership
0.027%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Diametric Capital, LP holds $50,262,099 across 63 Biotechnology names. GNLX ranks #61 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PGEN |
Precigen, Inc.
|
6,801,788 | $26,322,919 | |
| 2 | ABEO |
Abeona Therapeutics Inc.
|
611,520 | $2,739,609 | |
| 3 | VKTX |
Viking Therapeutics, Inc.
|
63,896 | $2,079,175 | |
| 4 | SLNO |
Soleno Therapeutics Inc
|
57,832 | $1,936,215 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
15,000 | $1,458,750 | |
| 6 | ENLV |
Enlivex Ltd.
|
1,483,178 | $1,379,355 | |
| 7 | ABVX |
Abivax S.A.
|
10,000 | $1,113,500 | |
| 8 | OCUL |
Ocular Therapeutix, Inc
|
125,000 | $1,058,750 |
All Filings in GNLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,403 | 12,150 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||